To determine the safety profile of the CD155.CAR T cells and to further discuss their translation into the clinic, the non-tumor-bearing mice in each group received CD155.CAR-T, CD19.CAR-T, or Mock-T cells infused via the tail vein. Here, CD19 is linked to neoplasm.